REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $31,746,062 | +118.5% | 311,358 | +94.8% | 0.15% | +108.3% |
| Q1 2023 | $14,530,471 | +75.6% | 159,816 | -26.6% | 0.07% | +56.5% |
| Q4 2022 | $8,276,008 | +3.0% | 217,847 | -31.9% | 0.05% | +7.0% |
| Q3 2022 | $8,036,000 | +20.8% | 319,780 | +46.1% | 0.04% | +26.5% |
| Q2 2022 | $6,651,000 | -20.2% | 218,853 | -13.9% | 0.03% | -27.7% |
| Q1 2022 | $8,331,000 | -2.1% | 254,305 | -21.2% | 0.05% | 0.0% |
| Q4 2021 | $8,507,000 | -15.3% | 322,586 | +354.4% | 0.05% | -32.9% |
| Q2 2021 | $10,047,000 | +503.8% | 70,990 | +325.4% | 0.07% | +483.3% |
| Q1 2021 | $1,664,000 | +300.0% | 16,689 | +479.5% | 0.01% | 0.0% |
| Q1 2020 | $416,000 | -86.0% | 2,880 | -80.2% | 0.01% | -79.3% |
| Q4 2019 | $2,971,000 | +558.8% | 14,532 | +175.6% | 0.06% | +314.3% |
| Q1 2019 | $451,000 | – | 5,272 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
| Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
| Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
| MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
| Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
| Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
| Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
| AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |